Kakinada Penicillin-G plant at heart of India's import-cut push, says Andhra Minister Nara Lokesh

Andhra Pradesh Minister for Information Technology and Human Resources Development Nara Lokesh said on Friday that the Penicillin-G manufacturing facility of Lyfius Pharma Private Limited in the Kakinada Special Economic Zone (SEZ) was helping India reduce its dependence on imported raw materials for essential antibiotics.

In a post on X, Mr. Lokesh said he was proud that Kakinada was at the heart of India's return to making Penicillin, and that Andhra Pradesh was ready to play a key role in building a self-reliant pharmaceutical supply chain for the nation. He also thanked Prime Minister Narendra Modi. Mr. Lokesh is a minister in the Telugu Desam Party-led State government.

His remarks came shortly after the Prime Minister posted on X that Penicillin-G was being made in India again, describing it as a step towards strengthening the domestic pharmaceutical industry and reducing dependence on imported raw materials for medicines.

In an official release issued by the Union government, Mr. Modi was quoted as saying, "With over ₹5,000 crore invested and around 40 projects initiated under the Production Linked Incentive (PLI) scheme, India is taking important steps towards 'Aatmanirbharta' in pharmaceutical manufacturing."

The Prime Minister had virtually inaugurated the Lyfius Pharma facility at the SEZ in Thodangi Mandal on October 29, 2024. According to the company, it has invested ₹2,500 crore under the PLI scheme, and the plant has an annual production capacity of 1,500 tonnes. The investment and capacity figures were stated by the company and the Union government.

Why Penicillin-G matters

Penicillin-G, often called Pen-G, is a key starting material and active pharmaceutical ingredient used to produce several widely used antibiotics, including semi-synthetic penicillins such as amoxicillin. India was among the early producers of the ingredient, but bulk manufacturing gradually shifted abroad, largely to China, leaving Indian drugmakers dependent on imports for this raw material.

That dependence became a matter of public concern during global supply disruptions, when concerns were raised about the availability and pricing of essential medicines. Successive Union governments have since sought to revive domestic production of fermentation-based active pharmaceutical ingredients through incentive schemes.

Under the PLI scheme for pharmaceuticals, the Union government offers incentives to manufacturers to set up production capacity for raw materials and key starting materials for essential drugs. Officials have described the scheme as a way to strengthen the supply chain for medicines used in routine treatment as well as in public health programmes.

What is not yet clear

The plant's actual contribution to reducing import dependence will depend on factors such as sustained production levels, cost competitiveness against imported material, quality clearances from regulators, and compliance with environmental norms for fermentation-based manufacturing. Details on current capacity utilisation and the buyers of the material produced at Kakinada were not available in the statements issued on Friday.

Neither the company nor the State government indicated whether the facility is already supplying Penicillin-G commercially to antibiotic manufacturers, or whether output is being stockpiled or exported.

Political attention on a local project

Friday's exchange between the State minister and the Prime Minister put a spotlight on a single industrial unit in Kakinada, a port city that has been projected as a hub for pharmaceutical and industrial investment in Andhra Pradesh. Both leaders presented the facility as evidence of progress in domestic manufacturing, a theme that has featured prominently in national policy messaging in recent years.

The Union government has not released an independent assessment of how much of India's Penicillin-G requirement is now met domestically. For readers, the practical question is whether a steady domestic supply of the raw material translates into more reliable and affordable access to common antibiotics — a link that will be tested only as production at such plants scales up and is sustained over time.